The FDA couldn't create a monopoly, so the Kynmaro approval was a 100% certainty since the panel voted in favor of it. This is little more than a formality.
AEGR shareholders WANT Kynmaro approved as it makes it a much higher probability insurers will cover both drugs, and guards against any possible lawsuits in the future (as has historically been the case when there was only 1 treatment on the market).
But FDA approval and commercial success are worlds apart.
There are still serious concerns about Kynmato's link to cancer, but patients need alternatives, so this is a very good thing. The winner in this race is patients!
Patients prefer lomitapide 93 out of 100, and Doctors will select lopitamide by an even higher margin. Go poll them if you have any doubts. Doctors will use lopitamide first, and only switch to Kynmaro as a last resort. Therefore, it won't make any difference to AEGR.